PPFIBP1 Antibody

Basic Research Questions

• What is PPFIBP1 and why is it important in cancer research?

PPFIBP1 (PTPRF interacting protein, binding protein 1), also known as Liprin-beta-1, is a 114 kDa protein that belongs to the LAR protein-tyrosine phosphatase-interacting protein (liprin) family. It plays significant roles in:

• Regulation of focal adhesion disassembly

• Cell migration and invasion

• Cancer metastasis and chemoresistance

Recent studies have highlighted PPFIBP1's importance in various cancers:

In experimental models, higher PPFIBP1 expression correlates with poorer prognosis in glioma patients and multiple myeloma patients, making it an important research target for therapeutic development .

• What applications are PPFIBP1 antibodies suitable for?

PPFIBP1 antibodies have been validated for multiple experimental applications:

These applications enable comprehensive analysis of PPFIBP1 in various experimental contexts, from protein expression levels to interaction studies and cellular localization .

• How should I select the most appropriate PPFIBP1 antibody for my research?

Selection depends on your specific research questions and experimental design:

For studying specific signaling pathways:

• When investigating NF-κB pathways in MM, use antibodies validated in myeloma cells

• For FAK/Src/JNK pathway studies in glioma, select antibodies validated in glioma cell lines

Always validate antibody specificity in your experimental system using appropriate positive controls (HepG2, U2OS cells) and negative controls (liver tissue) .

• What are the optimal storage and handling conditions for PPFIBP1 antibodies?

Proper storage and handling are crucial for maintaining antibody performance:

Additional handling considerations:

• Some preparations contain 0.1% BSA in small volume formats (20μL)

• For optimal performance in immunofluorescence, equilibrate antibody to room temperature before use

• Centrifuge vial briefly before opening to recover all material

Improper storage can lead to reduced signal intensity and potential non-specific binding in immunoassays .

• What cell lines and tissues show positive expression of PPFIBP1?

PPFIBP1 exhibits a tissue-specific expression pattern:

Note: PPFIBP1 expression is widely distributed across tissues but notably absent in liver, making liver tissue an excellent negative control for antibody validation studies .

Advanced Research Questions

• How can I validate the specificity of PPFIBP1 antibodies for my experimental setup?

A comprehensive validation strategy includes multiple approaches:

Advanced validation for functional studies:

• Perform immunodepletion experiments to confirm antibody specificity

• Use CRISPR/Cas9-generated PPFIBP1 knockout cells as negative controls

• Compare results with alternative antibodies targeting different epitopes

• Include phosphorylation-specific controls when studying signaling pathways

Enhanced validation techniques as demonstrated by Sigma's HPA001924 antibody include orthogonal RNAseq validation to confirm specificity .

• What are the optimal immunofluorescence protocols for PPFIBP1 subcellular localization studies?

For accurate subcellular localization of PPFIBP1:

Optimization tips:

• For co-localization studies with focal adhesion markers, use antibody concentration at the lower end of the recommended range to minimize antibody saturation effects

• Include appropriate controls (primary antibody omission, isotype control)

• U2OS cells are ideal positive controls for IF/ICC optimization

• For cancer cell studies, ensure fixation conditions don't disrupt focal adhesion structures

For cellular compartment verification, co-stain with markers for cytosol, plasma membrane, and presynaptic active zone .

• How do I design experiments to investigate PPFIBP1's role in chemoresistance of multiple myeloma?

Based on recent research , a comprehensive experimental design should include:

Key antibodies required:

• Anti-PPFIBP1 (1:1000, validated in MM cells)

• Anti-RelA (1:1000, Cell Signaling Technology)

• Anti-P-RelA (1:1000, Cell Signaling Technology)

• Anti-PARP (for apoptosis detection)

For mechanistic insights into NF-κB pathway activation, include analysis of:

• RelA stabilization using cycloheximide chase assays

• RelA nuclear translocation via immunofluorescence

• NF-κB target gene expression by qRT-PCR

• What are the best co-immunoprecipitation approaches for identifying PPFIBP1 binding partners?

Based on published methods , optimal co-IP strategies include:

Protocol specifics:

• Prepare cell lysates in NETN buffer (20 mM Tris-HCl pH 8.0, 100 mM NaCl, 1 mM EDTA, 0.5% NP-40) with protease and phosphatase inhibitors

• Pre-clear lysates with Protein A/G beads for 1 hour at 4°C

• Incubate pre-cleared lysates with anti-PPFIBP1 antibody overnight at 4°C

• Add Protein A/G beads and incubate for 2-4 hours at 4°C

• Wash 4-5 times with lysis buffer

• Elute bound proteins with SDS sample buffer at 95°C for 5 minutes

For studying specific interactions:

• PPFIBP1-RelA interaction: Use HepG2 cells for optimal results

• PPFIBP1-SRCIN1 interaction: Important for studying glioma invasion mechanism

• For reverse IP, 293T cells show good results with PPFIBP1 antibodies

• What are the considerations for using PPFIBP1 antibodies in studying the FAK/Src/JNK signaling pathway in glioma?

Based on research findings , key considerations include:

Experimental design for signaling studies:

• Establish PPFIBP1 overexpression and knockdown cell models

• Assess effects on cell migration/invasion

• Analyze activation status of FAK/Src/JNK pathway components

• Perform rescue experiments with pathway inhibitors

• Evaluate MMP-2 expression as a downstream effector

Important controls:

• Include both gain-of-function and loss-of-function models

• Use time-course analyses to capture transient signaling events

• Include pathway inhibitors to confirm specificity

• Compare results in multiple glioma cell lines to ensure robustness

• How can I design immunohistochemistry experiments to study PPFIBP1 expression in clinical cancer specimens?

Based on published protocols , a comprehensive IHC strategy should include:

Critical methodology considerations:

• Include positive controls (tissues with known PPFIBP1 expression)

• Include negative controls (liver tissue, primary antibody omission)

• Perform double-blind scoring to minimize bias

• Stratify patients into PPFIBP1-Low (scores 0-1) and PPFIBP1-High (scores 2-3) groups

For clinical correlation studies:

• In glioma specimens, correlate PPFIBP1 expression with tumor grade and invasion status

• In MM specimens, correlate with treatment response and survival

• Consider using tissue microarrays for high-throughput analysis

• What are the best approaches for multiplexed detection of PPFIBP1 and its signaling partners?

For comprehensive pathway analysis:

Protocol considerations for multiplex immunofluorescence:

• Use antibodies from different host species when possible

• If using same-species antibodies, employ direct labeling or sequential staining with intermediate blocking

• Include spectral controls to verify signal separation

• Use appropriate nuclear and membrane markers for spatial context

Key protein combinations for PPFIBP1 pathway studies:

• For NF-κB pathway: PPFIBP1 + RelA + P-RelA

• For FAK pathway: PPFIBP1 + FAK + p-FAK + Src + p-Src

• For metastasis studies: PPFIBP1 + SRCIN1 + integrins (α3, α4, β8)

• For invasion studies: PPFIBP1 + MMP-2

• How can I analyze PPFIBP1 expression data from public databases for cancer research?

Based on published approaches :

Analytical approaches:

• Stratify patients into high vs. low PPFIBP1 expression groups

• Correlate PPFIBP1 expression with clinical parameters (survival, treatment response)

• Analyze PPFIBP1 expression across molecular subtypes (e.g., mesenchymal vs. classical gliomas)

• Perform gene co-expression analysis to identify functionally related genes

For integrative analysis:

• Compare PPFIBP1 mRNA and protein expression levels

• Correlate PPFIBP1 with pathway activation signatures

• Analyze PPFIBP1 across cancer types to identify common mechanisms

• Use single-cell RNA-seq data to identify cell populations with high PPFIBP1 expression